Daisaku Yamada, Sumera Rizvi, Nataliya Razumilava, Steven F. Bronk, Jaime I. Davila, Mia D. Champion, Mitesh J. Borad, Jorge A. Bezerra, Xin Chen, Gregory J. Gores – 7 January 2015 – Cholangiocarcinoma (CCA) is a lethal hepatobiliary neoplasm originating from the biliary apparatus. In humans, CCA risk factors include hepatobiliary inflammation and fibrosis. The recently identified interleukin (IL)−1 family member, IL‐33, has been shown to be a biliary mitogen which also promotes liver inflammation and fibrosis. Our aim was to generate a mouse model of CCA mimicking the human disease.

Bani Mukhopadhyay, Kornel Schuebel, Partha Mukhopadhyay, Resat Cinar, Grzegorz Godlewski, Keming Xiong, Ken Mackie, Martin Lizak, Qiaoping Yuan, David Goldman, George Kunos – 7 January 2015 – Hepatocellular carcinoma (HCC) has high mortality and no adequate treatment. Endocannabinoids interact with hepatic cannabinoid 1 receptors (CB1Rs) to promote hepatocyte proliferation in liver regeneration by inducing cell cycle proteins involved in mitotic progression, including Forkhead Box M1.

Dawn M. Torres, Stephen A. Harrison – 6 January 2015

Barbara Schroeder, Ryan J. Schulze, Shaun G. Weller, Arthur C. Sletten, Carol A. Casey, Mark A. McNiven – 6 January 2015 – Autophagy is a central mechanism by which hepatocytes catabolize lipid droplets (LDs). Currently, the regulatory mechanisms that control this important process are poorly defined. The small guanosine triphosphatase (GTPase) Rab7 has been implicated in the late endocytic pathway and is known to associate with LDs, although its role in LD breakdown has not been tested.

Sommer E. Gentry, Eric K. H. Chow, Allan Massie, Xun Luo, David Zaun, Jon J. Snyder, Ajay K. Israni, Bert Kasiske, Dorry L. Segev – 31 December 2014 – Whether the liver allocation system shifts organs from better performing organ procurement organizations (OPOs) to poorer performing OPOs has been debated for many years. Models of OPO performance from the Scientific Registry of Transplant Recipients make it possible to study this question in a data‐driven manner.

Coby Annema, Petrie F. Roodbol, Roy E. Stewart, Robert J. Porte, Adelita V. Ranchor – 30 December 2014 – After liver transplantation, recipients often experience psychological problems that are influenced by demographic, personal, and transplant‐related variables. However, because previous studies have mostly reported on psychological problems and their influencing factors in the first years after transplantation, less is known about their prevalence and influence in the long run.

Arun J. Sanyal, Scott L. Friedman, Arthur J. McCullough, Lara Dimick‐Santos – 29 December 2014 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality.

Arun J. Sanyal, Scott L. Friedman, Arthur J. McCullough, Lara Dimick‐Santos – 29 December 2014 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality.

Xavier Forns, Michael Charlton, Jill Denning, John G. McHutchison, William T. Symonds, Diana Brainard, Theo Brandt‐Sarif, Paul Chang, Valerie Kivett, Lluís Castells, Martín Prieto, Robert J. Fontana, Thomas F. Baumert, Audrey Coilly, Maria Carlota Londoño, François Habersetzer – 29 December 2014 – Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is associated with accelerated progression of liver disease, frequently leading to graft loss and early death.

Jean‐François Dufour – 29 December 2014